DIRS.INFO The most relevant business & tech news

☆ I tried making the viral Caesar chicken-crust pizza, and I get why the easy high-protein dish is so popular on TikTok
▼ + stars: | 2024-05-08 | by ( Terri Peters | ) www.businessinsider.com time to read: +1 min

I tried the high-protein, low-carb Caesar-salad chicken-crust pizza I keep seeing on TikTok. The dish uses canned chicken to make a low-carb, high-protein pizza crust and is easy to make. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . Millions of TikTok users have viewed Caesar-salad chicken-crust pizza videos in which creators share recipes and promise the viral dish tastes fresh and flavorful. So, I made the viral Caesar-salad chicken-crust pizza in my own kitchen — and my family and I were pleasantly surprised.

Persons: — Organizations: Service

☆ Medicare can now cover certain weight loss drugs in a big step for patients
▼ + stars: | 2024-03-21 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Medicare can start covering certain weight loss drugs for the first time — as long as they are approved for an added health benefit, the Centers for Medicare and Medicaid Services said Thursday. Medicare prescription drug plans administered by private insurers, known as Part D, currently cannot cover those drugs for weight loss alone. A provision of a 2003 law established that Medicare Part D plans can't cover drugs used for weight loss, but the program does cover obesity screening, behavioral counseling and bariatric surgery. A CMS spokesperson told CNBC last week that Medicaid programs would be required to cover Wegovy specifically for its new cardiovascular use. Around 1 in 5 state Medicaid programs currently cover GLP-1 drugs for weight loss.

Persons: Ozempic, Eli Lilly Organizations: Novo Nordisk, Medicare, Centers, Services, Drug, Food and Drug Administration, CVS, Aetna, International Foundation of Employee, CNBC, FDA Locations: London, Britain, U.S

☆ Oprah Winfrey tears up recounting her weight loss journey in primetime special
▼ + stars: | 2024-03-18 | by ( Megan Thomas | ) edition.cnn.com time to read: +3 min

CNN —It’s been nearly 13 years since “The Oprah Winfrey Show” came to an end, but for viewers of her weight loss special on Monday night, it likely felt like Winfrey’s talk show was back. “An Oprah Special: Shame, Blame and the Weight Loss Revolution” featured Winfrey doing what she proved for 25 seasons on “The Oprah Winfrey Show” she can do better than just about anyone else: bring people together and get them talking – and listening – to each other. Winfrey, too, shared the pain she has felt at times in her weight journey. “It’s not a matter of willpower.”The medical experts addressed potential side effects of weight loss medications and factors and risks that should be considered before taking it as part of a multiifaceted care plan. Winfrey spoke about her use of weight loss medication as one “tool” to manage her weight, combined with hiking, running, weight resistance training and eating a healthy diet.

Persons: CNN — It’s, Oprah Winfrey, ”, “, Winfrey, ” Winfrey, Scott Butsch, Amanda Velazquez, It’s, ” Butsch, “ It’s, Let’s Organizations: CNN, Obesity, Metabolic, Cleveland Clinic Locations: United States, Sinai, Los Angeles

☆ Thinking about taking new weight loss drugs? These are the big health risk decisions that will follow
▼ + stars: | 2024-02-28 | by ( Eric Rosenbaum | ) www.cnbc.com time to read: +6 min

In this article NOVO.B-DKLLYWWGWW Follow your favorite stocks CREATE FREE ACCOUNTAn injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. But will Americans trust the most iconic brand in the legacy weight-loss business to guide them into its future? "Big pharma was coming for weight loss, and if they didn't have a clinical angle, they would have run the risk of becoming an irrelevant company." "This is a new, incredibly powerful and effective class of pharmaceuticals that a lot of people will find help improve their health." watch nowRisks of overreliance on obesity drugs The risk is real that providers may use the medications and "forget about lifestyle," said John Batsis, an associate professor and nutrition expert at the University of North Carolina Chapel Hill's school of public health.

Persons: Eli Lilly’s, Brendan Mcdermid, Eli Lilly, —, Sima Sistani —, Sistani, Alex Fuhrman, Hallum, Fuhrman, Davidson, Linda Bolton Weiser, I've, Geoff Cook, Cook, John Batsis, Batsis Organizations: Reuters, Novo Nordisk, CNBC, Craig, pharma, University of North, University of North Carolina Chapel Locations: New York City, U.S, Herbalife, University of North Carolina

☆ Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
▼ + stars: | 2024-02-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

Victoria Klesty | ReutersThe insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly , have said supply woes likely won't go away anytime soon, as the popularity of those medicines continues to soar. Some Wall Street analysts project that the weight loss drug market could be worth $100 billion by the end of the decade. But both Novo Nordisk and Eli Lilly gave updates on positive supply developments to investors over the last week. Other forms of weight loss drugs could helpAlternative forms of weight loss drugs could also help alleviate supply constraints in the future.

Persons: Victoria Klesty, Eli Lilly, Cantor Fitzgerald, Louise Chen, Nordisk's Wegovy, Eli Lilly's Zepbound, Goldman Sachs, Jeff Friedman, Novo, Mike Segar, Eli, Catalent, Yves Herman Yves Herman, TD Cowen, Michael Nedelcovych, Anat Ashkenazi, Cantor Fitzgerald's Chen, Morgan Stanley, Eli Lilly's, George Frey Organizations: Novo Nordisk, CNBC, Nordisk's, University of Florida, Pfizer, AstraZeneca, Roche, Food, Nordisk, Company, FDA, Novo Holdings, Wegovy, REUTERS, Reuters, U.S Locations: Oslo, Norway, Novo, U.S, Branchburg , New Jersey, Brussels, Belgium, Catalent, Concord , North Carolina, North, Germany, Indiana, Denmark, France

☆ What to know about medications like Ozempic, Wegovy, Mounjaro and Zepbound for weight loss
▼ + stars: | 2024-02-03 | by ( Andrea Kane | ) edition.cnn.com time to read: +8 min

Editor’s note: Season 9 of the podcast Chasing Life With Dr. Sanjay Gupta explores the intersection between body weight and health. But anyone who has ever dieted can tell you that losing weight is hard and that long-term weight loss requires sustained effort, which can sometimes feel Herculean, even impossible. If you are considering starting one of these medications, Moreno recommends keeping these five facts in mind. “On average, with semaglutide, the weight loss average can be close to 15%. This is the time to start changing some eating patterns that will be beneficial for weight loss.

Persons: Sanjay Gupta, Ozempic, It’s, Jorge Moreno, Moreno, ‘ You’ve, ”, ” Moreno, “, Tirzepatide, Food and Drug Administration — “, They’re, ” They’re, —, “ It’s, GERD, ” It’s, ’ ” Moreno Organizations: CNN, Yale School of Medicine, LinkedIn, Food and Drug Administration

☆ 4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
▼ + stars: | 2024-01-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +12 min

We will go over them – but first, let me talk about what I learned at last week's JPMorgan Health Care Conference that I attended in San Francisco, and what it means to your portfolio. We know health care has a lot of angles too it. The previous CEO Roz Brewer was from Starbucks and struggled with the role that Walgreens plays in health care. You have to be following the transformation of Bristol-Myers, which is opening its wallet to buy a host of drug companies, including anti-psychotic firm Karuna. Health care is the way to go.

Persons: Regeneron, Pfizer, Eli Lilly, Dave Ricks, Lilly, donanemab, Lilly's, Zepbound, it's, Abbott, It's, Roche, Merck, Myers, ABT, Robert Ford, Tim Wentworth, He's, Roz Brewer, Wentworth, he'll, Brewer wasn't, Bob Bradway, Amgen, Vas Narasimhan, Sandoz, Karuna, Medtronic, Hugo, Morgan Stanley, Wells, Covid, Cramer's, Jim Cramer, Jim, Las Vegas Brendan Smialowski Organizations: Abbott Labs, Covid, Novartis, Amgen, Walgreens Boots Alliance, JPMorgan Health Care Conference, Humana, Drug Administration, Novo Nordisk, Dickinson Co, Bristol, Myers Squibb, Pfizer, Department, WBA, Walgreens, Starbucks, -, pharma, Merck, Keytruda, Horizon Therapeutics, Federal Trade Commission, Myers, BD, CVS Health, JPMorgan, Cramer's Charitable, CNBC, Consumer, AFP, Getty Locations: San Francisco, GLP, North Carolina, Europe, Cencora, Amgen, West, Bristol, Target, Las Vegas

☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
▼ + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.

Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23

☆ Bariatric Surgery at 16
▼ + stars: | 2023-10-31 | by ( Helen Ouyang | ) www.nytimes.com time to read: +4 min

It’s the exact opposite.” The number of teenagers who underwent bariatric surgery more than doubled nationwide between 2010 and 2017 and continues to rise. Seeley emphasizes that weight loss doesn’t simply result from a newly tiny stomach that limits how much people can eat. The crucial roles instead seem to be played by bile acids and antimicrobial peptides in the gut, each of which increase markedly after surgery; Seeley is still sorting out the exact mechanisms of their influence. “Why bariatric surgery works so well is because you’re changing lots of things at the same time,” Seeley says. Most important, bariatric surgery seems to reset, to a lower bound, the body weight that the brain tries to maintain.

Persons: Rodriguez, “, ”, Alexandra, ” Gabriela, ” Rodriguez, Thomas Inge, Randy Seeley, Seeley, ” Seeley, “ I’m, ” Inge, I’d, “ We’ve Organizations: Teen, National Institutes of Health, Lurie Children’s Hospital, University of Michigan Locations: United States, Chicago

Such forecasts have prompted a sell-off in a wide range of companies from makers of bariatric surgery devices to companies whose products address the health issues created by excess weight, from diabetes to sleep apnea. "The market is in a shoot-first, ask-questions-later mood when it comes to weight-loss drugs," said Nicholas Anderson, manager of the Thornburg International Growth Fund, which holds shares of Novo Nordisk. By contrast, the iShares U.S. Medical Devices exchange-traded fund has lost more than 22% in the last three months. Injectable weight-loss drugs, known as GLP-1 receptor agonists, are considered highly effective but are also expensive, costing more than $1,300 per month. "Overall, we'll see an increased interest in bariatric surgery, but that will get delayed in the short term."

Persons: Doctor Thomas Horbach, Wegovy, Nicholas Anderson, Eli Lilly, Kenneth Stein, Margaret Kaczor Andrew, William Blair, Michael Farrell, Jeff Jonas, Johnson, Myriam Curet, Ann Hynes, Hynes, David Gaffen, Manas, Michael Erman, Caroline Humer, Sonali Paul Organizations: Novo Nordisk, Healthcare, Growth Fund, Medical Devices, Boston, Gabelli Funds, Johnson, Reuters, Mizuho Securities, Manas Mishra, Thomson Locations: Germany, Munich, Danish, U.S, Boston, GLP, New York, Bengaluru

☆ AI, weight loss drugs and more: Portfolio manager names stocks to play 'new secular growth themes'
▼ + stars: | 2023-10-24 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

And then you overlay on top of that the emergence of two or three brand new secular growth themes," he said. CNBC Pro takes a look at the stocks he likes in three "brand new" areas of growth: obesity drugs, reshoring and artificial intelligence. Reshoring infrastructure Ayer sees bright spots in the reshoring theme too. The portfolio manager named tech giant Amazon as a good play of the AI wave. The way Ayer sees it, more companies in the U.S. are foraying into AI right now, compared to those in other parts of the world.

Persons: Sanjay Ayer, Ayer, He's bullish, —, Christina Cheddar Berk, Carmen Reinicke, Julie Coleman Organizations: CNBC Pro, WCM Investment Management, Equity Fund, Nordisk, Novo Nordisk, U.S . Food, Drug Administration, Tetra Tech, Canadian, Canadian Pacific, U.S Locations: U.S, China, Japan, India

☆ Robot maker Intuitive's sales miss as weight-loss drugs cut into bariatric surgery demand
▼ + stars: | 2023-10-19 | by ( Khushi Mandowara | ) www.reuters.com time to read: +2 min

Oct 19 (Reuters) - Intuitive Surgical (ISRG.O) missed analysts' estimates for quarterly sales on Thursday and flagged sagging demand for its robots used in bariatric surgeries amid the growing popularity of weight-loss drugs. Shares of the da Vinci surgical robots maker tumbled nearly 7.8% to $252 in trading after the bell. On Tuesday, Johnson & Johnson (JNJ.N) signaled a hit to sale of devices used to perform abdomen surgeries such as bariatric. Such patients will eventually become increasingly interested in bariatric surgery but this will get delayed in the short term, Curet said. Bariatric surgeries grew at modestly lower rate in third quarter compared to the previous quarter, financial head Jamie Samath said, adding the company was gaining market share in the surgical segment.

Persons: Johnson, Myriam Curet, Curet, Jamie Samath, Khushi, Sriraj Organizations: Thomson Locations: U.S, Bengaluru

☆ Corporate America weighs risks of the Ozempic effect
▼ + stars: | 2023-10-19 | by ( ) www.reuters.com time to read: +3 min

Walmart (WMT.N) expects revenues from its health and wellness products to increase in the second half of the year, mainly due to the popularity of weight-loss drugs. PepsiCo (PEP.O) Chief Financial Officer Hugh Johnston has said the company is "not seeing any impact" yet from the popularity of weight-loss drugs. Abbott Laboratories (ABT.N), which makes glucose monitoring products, has said that the market was overestimating the impact to its sales from growing popularity of the drugs. Abbott CEO Robert Ford has said that diabetes patients could end up using glucose monitors with the weight-loss drugs in the long term. DRUG DISTRIBUTORSCencora (COR.N), formerly called AmerisourceBergen, Cardinal Health (CAH.N) and McKesson (MCK.N) have flagged potential boost to revenues this year owing to the growing demand for weight-loss drugs.

Persons: George Frey, Eli Lilly's, Hugh Johnston, Johnson, Joseph Wolk, Robert Ford, Bhanvi, Mrigank Organizations: Novo Nordisk, Pharmacy, REUTERS, Walmart, PepsiCo, Abbott Laboratories, Insulet Corp, Cardinal Health, Thomson Locations: Provo , Utah, U.S, Bengaluru

☆ GLP-1 weight loss drugs are creating opportunities for these 2 stocks, investment advisor says
▼ + stars: | 2023-10-18 | by ( Weizhen Tan | ) www.cnbc.com time to read: +3 min

Developments surrounding the drugs, also popularly used for weight loss, have been disrupting anything from owners of dialysis centers to bariatric surgery providers and the food industry. But one investment advisor, Brian Krawez, president of Scharf Investments, says there are opportunities. "Many investors are concerned about the impacts of the GLP-1 drugs on a host of companies ranging from restaurants to consumer staples. Those mechanisms are the ones that help patients taking the drugs to lose weight and regulate their diabetes. They got roughly 35% market share, but a lot of people don't know the company," he said, adding that specialty pharmaceuticals — including the GLP-1 drugs —account for roughly 35% of the company's earnings.

Persons: Brian Krawez, Scharf, Mounjaro, Krawez, CNBC's, McKesson, It's, —, Christina Cheddar Berk, Julie Coleman Organizations: Scharf Investments, CNBC, Novo Nordisk, Walmart, Unilever, Unilever isn't Locations: GLP, U.S

The logo of Johnson & Johnson is seen on a Brussels' office of the company in Diegem, Belgium September 21, 2023. J&J raised its annual profit forecast, helped by strong sales from its pharmaceutical business, and shares of the U.S. healthcare conglomerate were off about 1%. Excluding its consumer health unit, J&J now expects 2023 adjusted profit of $10.07 to $10.13 per share, up from its previous view of $10.00 to $10.10. Sales at J&J's medical device unit came in at $7.46 billion, shy of Wall Street estimates of $7.58 billion. J&J finalized the biggest shake-up in its 137-year history in August with the spinoff, but retained a 9.5% stake in its iconic consumer health business.

Persons: Johnson, Yves Herman, J, Vamil Divan, Joseph Wolk, Ozempic, Wolk, Bhanvi Satija, Sriparna Roy, Patrick Wingrove, Shounak Dasgupta, Bill Berkrot Organizations: Johnson, REUTERS, Guggenheim Partners, Vamil, Reuters Graphics, J, Thomson, &' $, & $, & $ Locations: Brussels, Diegem, Belgium, Bengaluru, New York

The logo of Johnson & Johnson is seen on a Brussels' office of the company in Diegem, Belgium September 21, 2023. Investors are focused on how J&J, now a standalone pharmaceutical and medical devices company, will reach its goal of $57 billion in drug sales by 2025. Johnson & Johnson recorded a $21-billion gain in the third quarter from the spin-off of its consumer health unit. Stelara, J&J's top-selling anti-inflammatory drug, brought in sales of $2.86 billion in the quarter, above LSEG estimates of $2.61 billion. Excluding its consumer health unit, J&J now expects 2023 adjusted profit of $10.07 to $10.13 per share, compared with its previous outlook of $10.00 to $10.10 per share.

Persons: Johnson, Yves Herman, MedTech, Cantor Fitzgerald, Louise Chen, Stelara, Joseph Wolk, Wolk, J, Bhanvi Satija, Sriparna Roy, Patrick Wingrove, Shounak Dasgupta Organizations: Johnson, REUTERS, Innovative Medicine, Reuters, Thomson, & $, & $ Locations: Brussels, Diegem, Belgium, Stelara, U.S, United States, Bengaluru, New York

By comparison, a group of people who also dieted and exercised, but then received dummy shots, lost weight initially but then regained some, researchers reported Sunday in the journal Nature Medicine. Participants in both groups lost about 7% of their body weight, or almost 17 pounds (8 kilograms), during the diet-and-exercise phase. Those who received the drug went on to lose an additional 18.4% of initial body weight, or about 44 pounds (20 kilograms) more, on average. Nearly 29% of those taking the drug lost at least a quarter of their body weight, compared with just over 1% of those taking placebo. Side effects including nausea, diarrhea and constipation were reported more frequently in people taking the drug than those taking the placebo.

Persons: Mounjaro, ”, Thomas Wadden, Eli Lilly, it's, Caroline Apovian, wasn't, tirzepatide, “, Lilly Organizations: Nature, University, Pennsylvania, Brigham, Women's, Novo Nordisk, U.S . Food, Drug Administration, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S, ”

How GLP-1 drugs work Sorting through the facts reveals some likely winners and losers. LLY YTD mountain Eli Lilly shares year to date performance It is still early days for GLP-1 medications. Many have seen the rise of GLP-1 drugs as a threat to the medical device industry. Also, not all patients are able to tolerate GLP-1 drugs, which can cause side effects such as nausea. Among other medtech stocks, Plovanic sees GLP-1 drugs as an "incremental positive" for Dexcom, which makes continuous glucose monitors (CGMs), but an "incremental negative" for insulin pump makers like Insulet.

Persons: Insulet, Medtronic, Dexcom, BAX, NASH, Eli Lilly, Peter Verdult, Lilly, Eli Lilly aren't, Piper Sandler, Wegovy, Yasmeen Rahimi, Robbie Marcus, Marcus, hasn't, Baxter, David Low doesn't, William Plovanic, Craig Wong, Pan, Plovanic, Matt O'Brien, O'Brien, Rippling, Simeon Gutman, Morgan Stanley, Gutman, — CNBC's Michael Bloom Organizations: Novo Nordisk, Baxter International, Baxter, GLP, Citi, Novo, Bank of America, Viking Therapeutics, Pharmaceuticals, Pfizer, Amgen, Companies, Fisher, Reuters, Inspire, Systems, JPMorgan, RBC Capital, Walmart, underperformance Locations: GLP, U.S, DaVita, ResMed

☆ How is the rise of GLP-1 weight loss drugs affecting market action? Jim Cramer explains
▼ + stars: | 2023-10-11 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

CNBC's Jim Cramer on Wednesday explained how GLP-1 drugs are influencing market action. GLP-1 drugs were initially approved to treat diabetes, but many found off-label use to help with weight loss. Popular GLP-1 drugs include Eli Lilly 's Mounjaro and Novo Nordisk 's Wegovy, the latter of which has been approved by the Food and Drug Administration for weight loss management. Even though it seems early to asses the impact of these drugs, they are already affecting stocks, Cramer said. Intuitive Surgical also saw shares slide when executives noted slowed growth in bariatric surgeries last quarter, potentially due to increased use of GLP-1 drugs.

Persons: CNBC's Jim Cramer, there'll, Eli Lilly, Cramer, Abbott Labs —, Lilly's Mounjaro Organizations: Novo Nordisk, Food and Drug Administration, Abbott Labs

☆ How the weight loss boom could impact the real estate market
▼ + stars: | 2023-09-26 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

NNN YTD mountain NNN REIT shares have fallen more than 22%. If that vision comes to pass, it could boost apartment operators such as Equity Residential , Avalonbay Communities and Apartment Income REIT , among others. PEAK YTD mountain Healthpeak shares are down 26% since January and hit a 52-week low Tuesday. Healthpeak shares hit a 52-week low on Tuesday, while Welltower shares shed more than 2%. Healthpeak shares are down more than 26% over the same period.

Persons: Jefferies, Jonathan Petersen, Petersen, Simon, Morgan Stanley, — CNBC's Michael Bloom Organizations: Federal Realty Investment Trust, Equity Locations: U.S, Canada

☆ You Won’t Lose Weight on Ozempic Forever
▼ + stars: | 2023-09-18 | by ( Dani Blum | More About Dani Blum | ) www.nytimes.com time to read: +2 min

But doctors say some people seek out these drugs to lose as much weight as possible — and are dismayed and disillusioned when they stop. When they do, they tend to regain the weight they lost. Medications like Ozempic mimic a naturally occurring hormone and slow the emptying of the stomach, so that we feel fuller, faster and for longer. In clinical trials of semaglutide, the compound in Ozempic and Wegovy, people with diabetes have tended to lose less weight, less quickly, than people who did not have the condition, Dr. Hagan said. A small proportion of those who take these drugs won’t lose weight at all, he added.

Persons: ” Ms, Meinecke, Scott Hagan, Hagan, Andrew Kraftson Organizations: University of Washington, Michigan Medicine

A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. REUTERS/Jim Vondruska/Illustration/File Photo Acquire Licensing RightsFRANKFURT, Aug 24 (Reuters) - Supplies of Novo Nordisk's (NOVOb.CO) popular weight-loss drug Wegovy are limited in Germany less than a month after its launch in Europe's largest drug market, major drug distributors and doctors told Reuters. The volumes of the weekly injection that the Danish drugmaker has delivered to the country so far have fallen short of strong demand, the wholesalers said. "Demand is by far exceeding the available volumes," a spokesperson for Noweda, which has almost a quarter of the German drug wholesale trade, told Reuters, adding the problem was nationwide. The distributors, which act as go-betweens for drug companies and pharmacies, declined to give details of volumes.

Persons: Jim Vondruska, Thomas Horbach, Sanacorp, Pharmahandel, Pharma Privat, Helios St, Elisabeth Klinik, Jodok Fink, ”, Ludwig Burger, Maggie Fick, Josephine Mason, Mark Potter Organizations: REUTERS, Rights, Reuters, Noweda, Novo, Pharma, Thomson Locations: Chicago , Illinois, U.S, Novo, Germany, Europe, Munich, Oberhausen, Freiburg, Frankfurt, London

☆ As weight loss drug stocks rallied on a landmark study, these stocks were over sold, analysts say
▼ + stars: | 2023-08-11 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +8 min

However, the pharmaceutical companies are making the case that weight loss can improve health, and possibly lower health-care costs over time. But analysts have said the news isn't all bad for such stocks, and many were fell too low on Tuesday. Deutsche Bank analyst Imron Zafar estimated Thursday that bariatric surgery accounts for about 5% of Intuitive Surgical's U.S. robotic surgery business, but has been driving much of the company's growth. Some of the surgeons Zafar spoke with said any drop off in bariatric surgery was likely to be offset by increased use of the robot for other procedures. But they expect the drugs will remain necessary because GLP-1 drugs have yet to show they improve fibrosis, which is associated with NASH.

Persons: nonalcoholic steatohepatitis, NASH, Abbott, Robbie Marcus, Marcus, Marcus doesn't, Goldman Sachs, Goldman, Stryker, Smith, Zimmer Biomet, Bariatric, Imron Zafar, Zafar Organizations: Novo Nordisk, Abbott Laboratories, CNBC, JPMorgan, Companies, Inspire Medical Systems, Resmed, Philips, Nephew, Deutsche Bank, Madrigal Pharmaceuticals, Sagimet Biosciences, Akero Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, Madrigal Locations: U.S

☆ Why this landmark cardiac study means a bigger market for Lilly's blockbuster weight loss drug
▼ + stars: | 2023-08-09 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

A landmark study of the cardiovascular benefits of weight loss drug Wegovy is being seen as a pivotal step toward broadening access to these drugs. The drug, also known as tirzepatide, is expected to be approved for weight loss by the Food and Drug Administration by year-end. Notably, Medicare does reimburse obese patients for weight loss surgery, but Mounjaro has been able to help patients realize an average weight loss that approaches the typical success of bariatric procedures. If CMS is able to reimburse patients for weight loss treatment that would significantly increase access, boosting sales. "This is the first time a weight [loss] medicinal intervention has shown to have cardiovascular risk reduction.

Persons: enrollees, Eli Lilly, Lilly, Akash Tewari, NVO, Tewari, Wells, Mounjaro, Mohit Bansal, Robert Califf, Goldman Sachs, Chris Shibutani, Shibutani, Goldman, Refinitiv, Morgan Stanley, comorbidities, Bansal Organizations: Nordisk's Ozempic, Centers for Disease Control, Food and Drug Administration, Jefferies, Medicare, Services, GLP, STAT, Goldman, Lilly, Novo Nordisk, BMI, Novo Locations: U.S, GLP, Tuesday's

☆ Insurers face long road, high cost to cover obesity drugs after promising Wegovy heart health data
▼ + stars: | 2023-08-09 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

There is likely a long way to go before the U.S. sees increased insurance coverage for obesity drugs. While the trial results demonstrate that obesity drugs may have significant health benefits beyond shedding unwanted pounds, organizations representing U.S. insurers emphasized that the data is still preliminary. "Health insurance providers will continue to analyze new evidence as it becomes available," he added. Ceci Connolly, CEO of the Alliance of Community Health Plans, acknowledged the promise of the data but said "outrageous prices should give everyone pause." The organization represents regional, community-based health plans that cover more than 18 million Americans across the U.S.

Persons: Jim Vondruska, Wegovy, Eli Lilly, David Allen, Ceci Connolly, Jared Holz, It's, Debra Tyler's, Joe Buglewicz, Eduardo Grunvald, George Frey, UCSD's Gunvald, Eli, Ethan Lazarus, Lazarus Organizations: Reuters Novo Nordisk, Novo Nordisk, America's Health, Alliance of Community Health, U.S, Drugs, Pfizer, Medicare, CVS, Aetna, CNBC, Washington Post, Getty, UCSD Health's Center, International Foundation of Employee, University of Texas System, UTS, Novo, Reuters, Obesity Medicine Association, New England, of Medicine Locations: Chicago , Illinois, U.S, Mizuho, Killingworth, Conn, Texas

Search resuls for: "Bariatric"

25 mentions found